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Combined inhalation of nitric oxide and oxygen in
patients withmoderate to severe COPD: e¡ect on
blood gases
F.KANNIESS, R. A. JOº RRES ANDH.MAGNUSSEN
Hospital Grosshansdorf,Center for Pneumology and Thoracic Surgery,D-22927 Grosshansdorf,Germany
Abstract Inhalednitricoxide (NO) hasbeenreportedto improve oxygenationinpatientswith COPDif administered
in combinationwith oxygen (O2).Little, however, is known aboutthe variability of these e¡ects and the potential in£u-
ence of body position. Twenty-six spontaneously breathing patients with moderate to severe COPD inhaled clean
air,O2(FiO2, 0?29), 5 ppm NO, 5 ppm NOO2,10 ppm NOO2,10 ppm NO, and again clean air in an upright position.
Blood gas analysis from arterialized capillary blood was performed after each inhalation.Tests were repeated on dif-
ferent days to assess the variability of the response. Furthermore, eight patients were studied in both upright and
supine position while inhaling 5 ppm NO in the presence or absence supplemental O2. As compared to clean air,NO
led to a mean decrease in PaO2 ofÿ0?9mmHgat 5 ppm and ofÿ2? 8mmHgat10 ppm NO.Similarly,NOO2 led to a
dose-dependent fall in PaO2 of ÿ1?8 and ÿ3?6mmHg, respectively, as compared to O2. Average within-subject
variation (SD) of the e¡ects elicited by 5 and 10 ppm NO was 2?4 and 2?3mmHg without additional O2, and 4?7and
5?3mmHgwith O2.The e¡ects of 5 ppm NOO2 di¡ered signi¢cantly between upright and supine position; as com-
pared to O2 alone, mean (SD) changes were ÿ3?775?8 vs. 1?174?9mmHg, respectively. Our ¢ndings suggest
thatthe addition of NO to inhaled oxygen, when given in anupright position, does not lead to an improvementof PaO2
in patients with moderate to severe COPD. Furthermore, it turned out that it was not possible to de¢ne responders
and non-responders to inhaled NO on an individual basis, since the variability of the responseswas similar to themean
e¡ect.r2001Harcourt Publishers Ltd
doi:10.1053/rmed.2001.1186, available online athttp://www.idealibrary.comon
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In 1980 Furchgott and Zawadzki revealed that mamma-
lian cells are capable of producing a potent vasodilator
which was called endothelium-derived relaxing
factor (EDRF) (1). Later studies suggested that EDRF is
identical to nitric oxide (NO) (2,3). Therefore the
potential e¡ect of the inhalation of NO was studied
in a number of diseases involving disorders of vascular
tone or ventilation^perfusion mismatching, such
as adult respiratory distress syndrome (ARDS) (4),
primary pulmonary hypertension (5), pulmonaryReceived14 June 2000 and accepted in revised form13 March 2001.
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862; E-mail: f.kanniess@pulmoresearch.de¢brosis (6) or chronic obstructive pulmonary disease
(COPD).
In COPD, hypoxaemia is a common phenomenon, pri-
marily as a consequence of ventilation^perfusion mis-
match; there is no evidence on hypoxaemia owing to
increased intrapulmonary shunt and di¡usion impair-
ment (7). Based on this, it has been suggested that inha-
lation of vasoactive compounds such as NO might
in£uence the ventilation^perfusion ratio and thereby al-
ter the level of oxygenation.
In one of the initial studies on inhaled NO in
COPD, BarberaØ et al. (8) found that breathing of
40ppm NO led to a worsening of pulmonary gas
exchange as indicated by a decrease in arterial oxygen
pressure (PaO2). This was explained by an increase in
blood £ow through poorly ventilated alveolar units. In
contrast, pulmonary artery pressure and pulmonary
TABLE 1. Patients’characteristics
Mean Range
Age (years) 6777?16 50ÿ79
Bodymass index 25?174?43 16ÿ34
FEV1% (pred) 33?5711?0 15ÿ58
FEV1VC (%) 43?4711?7 30ÿ66
RV (% pred) 207?6753?1 106ÿ320
DLCO (% pred) (n=20) 55?8727?4 20ÿ92
PaO2 (mmHg) 58?477?31 46ÿ70
PaCO2 (mmHg) 45?476?69 36ÿ60
Pack-years 51730 5ÿ150
928 RESPIRATORYMEDICINEpredicted values and FEV1/VCratioo0?7.They were not
within an acute exacerbation and also showedno signs of
acute heart failure in ECG and echocardiography. Nine-
teen of the patients were ex-smokers and seven were
current smokers. Smoking was not allowed within 4h
before tests. All patients took inhaled b2-adrenoceptor
agonists, 15oral corticosteroids (nine of them in combi-
nation with inhaled steroids), 13 inhaled corticosteroids
only and12 theophylline.Medication was not withdrawn
before tests, however, in case of ongoing LTOT (n7 pa-
tients), oxygen delivery was discontinued for at least
30min prior to the tests. Baseline values of blood gases
and di¡using capacity were determined in the absence of
supplemental oxygen inhalation.
All measurements were performed at rest and in-
cluded determinations of PaO2 , PaCO2 and oxygen sa-
turation (SaO2). Patients inhaled clean air (free of nitric
oxide), O2 (FiO2), 0?29, 5 ppm NO, 5ppm NOO2,
10ppm NO and again clean air, in consecutive order.
Each period of inhalation lasted 10min. The order of
inhalations was not randomized owing to technical
reasons, in particular the long response time of the NO
analyser used. To assess whether the sequence of inha-
lations would have induced a trend that could mis-
takenly be interpreted as an e¡ect of inhalations, the
clean air inhalation was repeated at the end of the se-
quence. Inhalations were performed via a mouthpiece,
while patients had their nose clipped and were seated.
If PaO2 was judged too low during inhalation of 5ppm
NO, the NO concentration was not further increased
to 10ppm. At the end of each inhalation period, blood
gases were measured from hyperaemic capillary ear-
lobe blood, which has been demonstrated to produce
reliable results under resting conditions (13). Earlobe
blood was arterialized by application of an irritant
cream 10min prior to each test (Finalgons, Boehrin-
ger^Ingelheim, Germany). After each earlobe punc-
ture, the cream was applied again. SaO2 was measured
continuously (Nellcor Symphonie N-3000; Nellcor-
Bennett, Pleasanton,CA,U.S.A.) and data were fed into
a personal computer. For analysis of SaO2, the average
value over the last 5min of each10min inhalation period
was computed.
To assess the potential in£uence of body position, we
studied the combined inhalation of O2 and NO in both
sitting and supine position in eight patients (mean PaO2,
55?7 75?3mmHg; range, 47^63mmHg; FEV1 25?6
77?4% predicted). Patients inhaled clean air, O2 (FiO2,
0?29), 5ppm NO and 5ppm NOO2 via a mouthpiece
with clipped nose, in consecutive order. Again, the
duration of inhalation periods was 10min, and capillary
blood gas analysis was performed after each of them.
SaO2 was determined as described above. Measure-
ments in sitting and supine position were performed in
random order on the same day but at least 30min
apart.vascular resistance decreased signi¢cantly during inhala-
tion of NO.
In accordance with these ¢ndings, Yoshida et al. (9)
reported that inhalation of 2 ppm NO in normoxaemic
patients with COPD resulted in a deterioration of PaO2.
If, however, inhalation of NOwas combinedwith that of
O2 (1 O2min
ÿ1), PaO2 improved to 111?5mmHg as com-
pared to 91?4mmHg after O2 alone. Similary,German et
al. (10) investigated the e¡ect of inhaled NO added to
long-term oxygen therapy (LTOT). Addition of 5 ppm
NO to ongoing LTOT led to a signi¢cant increase in
PaO2 but therewas no further increasewhenconcentra-
tions were raised to 10 or 20ppm, thereby indicating a
ceiling e¡ect of NO.
Noteworthy, all available data have been obtained
with patients in supine or semi-supine position. Since it
is known that changes in body position can a¡ect
ventilation^perfusion matching (11), the results may not
be conferred to the upright position. It might be argued
that the clinical usefulness of NO within a long-term
treatment depends on the requirement that the
therapy is e¡ective during normal daytime activities,
which predominantly involve an upright position. Based
on these considerations, we studied the e¡ects of the in-
halation of NO and oxygen in patients withmoderate to
severe COPD, when patients were seated during
inhalation. Measurements were repeated on a second
day to assess the reproducibility of the e¡ects of NO
and to identify potential responders and non-respon-
ders.We also included a group of patients whowere stu-
died in both upright and supine position.
PATIENTSANDMETHODS
Study design
Twenty-six spontaneously breathing patients with
moderate to severe COPD were included (25males,
one female;mean age, 677?5 years; range, 50^79 years;
Table1).The diagnosis of COPDmet ERS criteria (12) and
all patients showed air£ow limitation, with FEV1o70% of
EFFECTOF INHALEDNITRICOXIDEANDOXYGENINCOPD 929The study was approved by the Ethics Committee of
the Chamber of Physicians of Schleswig^Holstein; all pa-
tients gave their informed consent.
Nitric oxide inhalation
NO was delivered through a non-rebreathing circuit
from a stock tank containing 450ppm NO in nitrogen
(Linde AG, Hamburg, Germany). The gas mixture was
prepared at a rate of 20 lminÿ1in a plastic bag from clean
air,O2 andNOat the inlet of a two-way valve connected
to the mouthpiece. The air not inhaled by the subjects
was removed through a bypass. Throughout the study,
oxygenwas given at a ¢xed ¢nal fractional concentration
of 0?29 FiO2 within a maximal error of70?005, which
was equivalent to the additional inhalation of 1
(70?006) lminÿ1 O2 at a ventilation rate of about
12 lminÿ1. The concentrations of inspired NO and NO2
were monitored continuously by a chemoluminescence
nitric oxide analyser (Monitor Labs 8840; Monitor Labs,
Gibsonia, PA, U.S.A.) which was calibrated daily using
5ppmNO calibration gas (Linde AG).The concentration
of O2 was assessed by an oxygen analyzer (O2-Test, Jae-
ger, Hoº chberg, Germany). Ventilation was measured in
the expiratory branch of the breathing system using a
pneumotachograph.
Data analysis
The analysis was performed in terms of PaO2, PaCO2,
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}Subgroups of patients studiedwith both 5 and10 ppmNO.
*Po0?05, **Po0?01vs. cleanairoroxygen, respectively;Po0?
Exact P-values are given inthe text.
Each inhalationperiod lasted10min and O2 wasgiven at a ¢nal cobtained after clean air inhalation at the beginning and
the end of the test was taken as baseline value of each
test. The e¡ects produced during the various NO and
O2 inhalationperiodswere then expressed as di¡erences
against this baseline value. For each individual subject,
mean values over the two study days were computed as
well as the corresponding standard deviations (SD); this
was done for both absolute values as well as di¡erences
to baselinevalues.Themeanvalue served as ameasure of
the individual response and the SD as a measure of intra-
individual variability. Individual mean values were then
averaged over the whole group of patients to obtain
overall mean values for each inhalation period. Similarly,
the squares (variances) of the individual standard devia-
tions were averaged and, afterwards, the square root
was taken to obtain a single SD as a measure of the aver-
age intra-individual variability. In addition, the SD be-
tween the individual mean values was computed, as an
index of inter-individual variability.
Statistical comparisons between the absolute values
or the e¡ects obtained in di¡erent inhalation periods
were performedby the paired t-test, using the individual
mean values.Clean air values were comparedwith the 5
and 10ppm NO values, and O2 values with the
O25ppm NO and O210ppm NO values. Further-
more, the results of the 5 and 10ppm inhalations in the
absence of supplemental O2 were compared to
each other using their di¡erences to the clean air
values. An analogous procedurewas followed for the va-
lues obtained in thepresence of supplementalO2. Statis-
tical signi¢cance was assumed for Po0?05.
We did not introduce Bonferrroni or other correctionsith COPD.Meanvalues7standard deviations are given













FIG. 1. E¡ectofnitricoxide andoxygenon PaO2.Blackbarsindicate themeanvalues for thosepatients that inhaledonly 5 ppmNO;
greybars indicate themeanvalues for those patients that inhaled 5 ppmNOand10 ppmNO.
930 RESPIRATORYMEDICINEfor multiplicity of testing, instead we gave P-values
explicitly.
RESULTS
All of the 26 patients inhaled 5ppmNO, and19 patients 5
as well as 10ppm NO. No adverse events such as head-
ache or increasing dyspnoea occurred during the inhala-
tion testings.Furthermore, no signs of acute right or left
ventricular dysfunction were observed on the following
days. The mean PaO2 at the beginning of the inhalation
periods were 55?6mmHg and 54?5mmHg at the begin-
ning and the end of the inhalation procedures, respec-
tively. Variability of PaO2 in terms of mean intra-
individual SD was1?4mmHg.
E¡ects of NOon arterial blood gases
Mean results obtained for PaO2 and PaCO2 are given in
Table 2 and individual results in Fig.1.
In the absence of supplemental oxygen, both levels of
inhaled NO produced a slight but statistically signi¢cant
decrease in PaO2 as compared to clean air. The average
magnitude of this decrease was 0?94mmHg at 5ppm
NO (P0?002) and 2?76mmHg at 10ppm NO
(Po0?0001). These values di¡ered signi¢cantly from
each other, indicating a dose-dependent e¡ect
(P0?002). Oxygen saturation showed a parallel courseto that of PaO2, although a statistically signi¢cant
reduction in SaO2 occurred only after inhalation of
10ppmNO as compared to clean air (Table 2).
In the presence of supplemental O2,NO also caused a
signi¢cant decrease in PaO2 as compared to the values
obtained with oxygen alone. PaO2 decreased by
1?84mmHg at 5ppm NO (P0?017) and by 3?59mmHg
at 10ppm NO (P0?007); these two values were
signi¢cantly di¡erent from each other (P0?026), again
indicating a dose-dependent deterioration of PaO2.
Again, SaO2 showed a course parallel to that of PaO2.
The e¡ects, however, were not signi¢cantly di¡erent
from zero.
Both levels of inhaled NO did not cause statistically
signi¢cant changes in PaO2 as compared to baseline
values (Table 2). This was true either in both the ab-
sence and presence of supplemental O2. Owing to a
technical fault, ventilation rates could not be assessed
in two patients. In those patients, however, in whom
ventilation rate was available (n24), there were no sta-
tistically signi¢cant di¡erences between inhalation re-
gimes. On average (7SD), ventilation rate was 12?8
73?2 lminÿ1.
Variability ofmeasurements
In the absence of supplemental O2, the average intra-in-
dividual SD of the change in PaO2 was 2?23mmHg after
FIG. 2. Variability of the nitric oxide e¡ects. Indicated are the di¡erences in PaO2 (mmHg) between 5 and10 ppm NO vs. clean air
(a, b) and between 5 ppmNOO2 and10 ppmNOO2 vs.O2 (c, d).
TABLE 3. E¡ect of body position on PaO2 (mmHg) dur-
inginhalationofcleanairoroxygenwithoutorwith 5 ppm
NOin patients with COPD (n8).Mean values and stan-
dard deviations are given.The changes in PaO2 during in-
halation of NOandO2 vs.O2 were statistically signi¢cant
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after 10ppm NO. In the presence of supplemental O2,
corresponding SD values were 4?65 and 5?33mmHg, re-spectively.To illustrate the relationship between the size
of the e¡ect and its variability, Fig. 2 shows the
e¡ects obtained on the two study days plotted against
each other.
Upright versus supine position
Eight patients were tested in both upright and supine
position. In the absence of supplemental O2, the mea-
surements performed in upright position showed no
statistically signi¢cant fall in PaO2 during breathing of
5 ppm NO as compared to clean air (Table 3).The same
was true for the measurements supine in position.
When 5ppm NO plus oxygen were inhaled in supine
position, mean PaO2 decreased by 3.73mmHg (NS) as
compared to oxygen alone. In the upright position,
there was a mean rise in PaO2 by 1?10mmHg (NS). The
di¡erence between both changes was on average
4?83mmHg and signi¢cantly di¡erent from zero
(Po0 ?05) (Fig. 3).
DISCUSSION
The inhalation of NO has been introduced as a potential
means to reduce pulmonary artery pressure and to im-
FIG. 3. E¡ectof bodyposition on PaO2.Indicated are the di¡erences in PaO2 between inhalation of NOand clean air (left side) and
between NOO2 and O2 (right side).The data showed a signi¢cant increase in PaO2 between supine and upright position during
breathing of NOand oxygen.Bars indicatemeanvalues.
932 RESPIRATORYMEDICINEprove oxygenation in a number of diseases including
primary pulmonary hypertension (5), ARDS (4) and
COPD (6,14,15). It has been used particularly in ARDS,
although recent controlled studies failed to demonstrate
a bene¢cial e¡ect in terms of survival rates
(16^18).
In patientswith severe COPD chronic hypoxaemia is a
major cause for the impairment in the quality of life, sur-
vival time and exercise tolerance (19). One study
demonstrated an annual increase in pulmonary artery
pressure (PAP) of 1?5mmHg in patients with COPD
(20), whereas supplemental oxygen therapy was capable
to invert this into an annual decrease by as much as
2?2mmHg per year. In accordance with these results,
long-term survival rates were found to be signi¢cantly
improved by LTOT in patients with severe COPD
(21,22). However in patients with less severe disease
LTOTmay have no e¡ect (23).
One of the major causes of hypoxaemia in COPD is
thought to be the ventilation^perfusion mismatch as in-
dicated, e.g. by themultiple inert gas elimination techni-
que (7). Vasodilators might deteriorate gas
exchange in patients with COPD; indeed, BarberaØ et al.
found a decrease in PaO2 when patients breathed NO
at rest (8). In contrast, exercise leads to an increase in
PaO2 during breathing of NO (24), probably becauseNO is preferentially diverted to alveolar units with
shorter time constants, hence facilitating NO delivery
to more preserved ventilation^perfusion ratios. This
would optimize pulmonary blood £ow and therefore
better ventilation and perfusion balance, other things
being equal. During exercise the inhaled NO might be
delivered to the well-ventilated and well-perfused com-
partments preferentially, whereas under resting condi-
tions it also might act in poorly ventilated and/or
perfused compartments. This raises the possibility
that simultaneous delivery of oxygen may reverse a
detrimental e¡ect of NO under resting conditions.
A number of authors have investigated the e¡ect of
combined inhalation of NO and O2 in spontaneously
breathing patients with moderate to severe COPD.
Yoshida et al. (9) found a signi¢cant increase in PaO2
of 20?1mmHg and a decrease in pulmonary artery
pressure of 1?7mmHg during breathing of 2 ppm NO
plus O2 as compared to O2 alone. The mean PaO2 of
the patients enrolled in this study was 72?3mmHg,
although baseline FEV1 was similar to that of patients
enrolled in the present study. A similar result has been
reported by German et al. (10) in patients with more
severe COPD (PaO2o60mmHg and mean FEV1 33?5%
predicted). Despite the bene¢cial e¡ects observed on
average, the authors also observed a large variability
EFFECTOF INHALEDNITRICOXIDEANDOXYGENINCOPD 933in individual responses. Some patients demonstrated a
marked improvement in PaO2 when NO was added to
oxygen, whereas others remained stable or even
showed a slight decrease in PaO2 values. Recently
published data by Ashutosh et al. (25) demonstrated
that in patients with severe COPD a 24-h inhalation of
NO and O2 resulted in a signi¢cant increase in cardiac
output and a decrease in pulmonary vascular resistance
as compared to LTOTalone. Noteworthy enough, how-
ever, PaO2 remained unchanged. Similar results were
found in patients with exacerbation of COPD under
mechanical ventilation (26).
It might be argued that the di¡erences between our
data and the previous results could be due to the fact
that patients inhaled NO via mouthpiece and not via
face mask or nasal cannula. However this approach
was chosen to administer well-de¢ned NO concentra-
tions independently from the patient’s breathing
pattern and we consider it unlikely that this procedure
signi¢cantly a¡ected PaO2 levels.Thewhole sequence of
measurements was performed under stable conditions
as indicated by the fact that PaO2 values obtained at the
beginning and the end of each test, when patients were
breathing clean air, were very similar.
It is well known that both ventilation and perfusion of
the lung depend on body position.Therefore, it is not a
priori guaranteed that the results obtained in
supine position are also true for upright position.When
subjectswere in upright position, the inhalation of 5ppm
NOplus oxygen led to a deterioration inPaO2.However,
when subjects changed their position to
supine, PaO2 slightly increased during inhalation of
5 ppm NO plus O2 as compared to O2 alone. The
concentration of 5ppm NO was selected as it had been
found previously bene¢cial when given in semi-recum-
bent position (10). Although the individual e¡ects were
not statistically signi¢cant but only the di¡erence
between those obtained for both positions, the result
might at least partially explain the discrepancy
between our and the previous data (9, 10). They suggest
that a redistribution of ventilation and perfusion
occurred in upright as compared to supine body
position. However, the data must be interpreted
cautiously owing to the large variability of responses.
Lung volume and/or cardiac function (27) may have
in£uenced the response to inhaledNO, as shownby pre-
vious authors in ARDS or ventilated patients.
However, the mechanism of these pathophysiological
changes remains unsettled, as we did notmeasure these
parameters.
Previous data indicating large di¡erences in response
between subjects did not allow to de¢ne responders
and non-responders through the reproducibility of
responses. To accomplish this, we performed repeated
measurements in the same subjects. As a result, the
variability was too large to allow a clear-cut de¢nitionof ‘responders’ even for the detrimental e¡ect
observed on average for upright position. It seems that
a potential therapeutic application of inhaled NO
requires (1) that there is a certain percentage of
patients with bene¢cial e¡ects and (2) that the e¡ect is
relatively independent from the NO concentration, ow-
ing to the di⁄cult to achieve a constant concentration
under varying breathing conditions.
In summary, our data indicate that in patients with
moderate to severe COPD inhalation of NO with and
without supplemental oxygen leads to a decrease in
PaO2 when patients are in upright position. These
changes in PaO2 were small, but nevertheless indicate
no improvement.
Furthermore, the intra-individual variability of the re-
sponses is large and of similar magnitude as the
average e¡ect.We conclude that treatment with inhaled
NO with or without supplemental oxygen is not a pro-
mising therapeutic approach to ameliorate hypoxaemia
in patients with COPD.
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